933a537c-4ba6-43ad-a51f-e68077ae65b5.jpeg
Give answers for 4th question for all clinical scenarios as a p-drug format
Reading File
Finding Sources
Searching the Web
P-drug format personal drug selection clinical scenarios WHO pharmacology
Now I have enough context. Let me provide comprehensive P-drug answers for all 15 clinical scenarios in the standard P-drug format (Diagnosis → Therapeutic Objective → Effective Drug Groups → P-drug choice with Dosage Form, Dosage, Duration, Instructions).
Question 4 — P-Drug List for All 15 Clinical Scenarios
The P-drug format follows this structure for each scenario:
- Diagnosis / Problem
- Therapeutic Objective
- Effective Drug Groups
- P-drug (chosen based on Efficacy, Safety, Suitability, Cost)
- Dosage form | Standard dose | Duration | Instructions
A. Toothache
| Step | Details |
|---|---|
| Diagnosis | Dental pain (odontogenic / pulpal pain) |
| Therapeutic Objective | Relieve pain; reduce inflammation |
| Effective Drug Groups | NSAIDs, Paracetamol, Opioid analgesics (severe) |
| P-drug | Ibuprofen |
| Rationale | Best analgesic + anti-inflammatory for dental pain; superior to paracetamol alone for inflammatory dental pain; OTC availability; low cost |
| Dosage Form | Tablet |
| Dose | 400 mg |
| Frequency | 3 times daily (every 8 hours) |
| Duration | 3-5 days (until dental treatment) |
| Instructions | Take after food; avoid in peptic ulcer disease; refer to dentist for definitive treatment |
B. Stable Angina Pectoris
| Step | Details |
|---|---|
| Diagnosis | Stable angina pectoris (effort-induced chest pain due to reversible myocardial ischaemia) |
| Therapeutic Objective | (1) Relieve acute angina attacks; (2) Prevent attacks; (3) Reduce mortality |
| Effective Drug Groups | Nitrates, Beta-blockers, Calcium channel blockers, Ranolazine |
| P-drug | Glyceryl Trinitrate (GTN) for acute relief + Atenolol for prophylaxis |
| Rationale | GTN: rapid-acting, highly effective for acute attack; Atenolol: reduces heart rate and O2 demand, proven mortality benefit, low cost |
| Dosage Form | GTN: sublingual tablet / spray; Atenolol: oral tablet |
| Dose | GTN 0.5 mg sublingual PRN; Atenolol 50 mg once daily (up to 100 mg) |
| Duration | GTN: as needed; Atenolol: long-term (indefinite) |
| Instructions | GTN: sit down, place under tongue; repeat in 5 min if no relief (max 3 doses); Atenolol: do not stop abruptly; add aspirin 75 mg + statin |
C. Productive Cough
| Step | Details |
|---|---|
| Diagnosis | Productive (wet) cough - usually acute bronchitis or URTI with mucus hypersecretion |
| Therapeutic Objective | Facilitate expectoration and clear airway secretions |
| Effective Drug Groups | Expectorants (Ammonium chloride, Guaifenesin), Mucolytics (Bromhexine, N-Acetylcysteine), Hydration |
| P-drug | Bromhexine |
| Rationale | Mucolytic - reduces viscosity of mucus; well tolerated; affordable; widely available |
| Dosage Form | Tablet |
| Dose | 8 mg |
| Frequency | 3 times daily |
| Duration | 5-7 days |
| Instructions | Drink plenty of fluids; steam inhalation helps; avoid antitussives (cough suppressants are contraindicated in productive cough) |
D. Dry Cough
| Step | Details |
|---|---|
| Diagnosis | Dry (non-productive) cough - irritative / post-viral or drug-induced (ACE inhibitor cough) |
| Therapeutic Objective | Suppress irritating cough reflex to provide symptomatic relief |
| Effective Drug Groups | Central antitussives (Codeine, Dextromethorphan), Peripheral antitussives (Benzonatate) |
| P-drug | Dextromethorphan |
| Rationale | Non-opioid central antitussive; no addiction potential unlike codeine; safe; OTC; low cost; no respiratory depression at therapeutic doses |
| Dosage Form | Syrup / Tablet |
| Dose | 15-30 mg |
| Frequency | Every 6-8 hours (3-4 times daily) |
| Duration | Up to 7 days |
| Instructions | If cough is ACE inhibitor-induced, switch to ARB; avoid in children <2 years; avoid with MAO inhibitors |
E. Rheumatoid Arthritis
| Step | Details |
|---|---|
| Diagnosis | Rheumatoid arthritis (chronic inflammatory autoimmune joint disease) |
| Therapeutic Objective | Reduce joint inflammation, relieve pain, prevent joint destruction, maintain function |
| Effective Drug Groups | NSAIDs (symptomatic), DMARDs (disease-modifying), Glucocorticoids, Biologics |
| P-drug | Methotrexate (DMARD) + Ibuprofen (symptomatic) |
| Rationale | Methotrexate: anchor DMARD for RA; proven to reduce radiological progression; cost-effective vs. biologics; most widely used first-line DMARD globally |
| Dosage Form | Methotrexate: tablet; Ibuprofen: tablet |
| Dose | Methotrexate 7.5-25 mg once weekly; Ibuprofen 400-600 mg TDS |
| Duration | Methotrexate: long-term (years); Ibuprofen: short-term as needed |
| Instructions | Methotrexate: always co-prescribe Folic acid 5 mg/week; monitor LFTs and CBC; avoid in pregnancy; Ibuprofen: take after food |
F. Diabetes Mellitus Type 1
| Step | Details |
|---|---|
| Diagnosis | Type 1 Diabetes Mellitus (absolute insulin deficiency due to autoimmune beta-cell destruction) |
| Therapeutic Objective | Achieve normoglycaemia; prevent acute (DKA) and chronic complications |
| Effective Drug Groups | Insulin (only effective group - oral agents are ineffective in T1DM) |
| P-drug | Insulin Human (Isophane + Regular) - Basal-Bolus regimen |
| Rationale | Insulin is the ONLY treatment for T1DM; human insulin is safer than animal insulin; combination of intermediate (NPH/Isophane) + short-acting (Regular) covers basal and prandial requirements |
| Dosage Form | Subcutaneous injection (vial + syringe or pen device) |
| Dose | 0.5-1 unit/kg/day total; split: ~50% basal (Isophane) + ~50% bolus (Regular, before meals) |
| Duration | Lifelong |
| Instructions | Rotate injection sites; monitor blood glucose; HbA1c target <7%; educate on hypoglycaemia recognition and management; dietary advice |
G. Diabetes Mellitus Type 2
| Step | Details |
|---|---|
| Diagnosis | Type 2 Diabetes Mellitus (insulin resistance + relative insulin deficiency) |
| Therapeutic Objective | Reduce blood glucose; prevent microvascular and macrovascular complications; weight neutrality or loss preferred |
| Effective Drug Groups | Biguanides, Sulfonylureas, DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 agonists, Thiazolidinediones, Insulin |
| P-drug | Metformin |
| Rationale | First-line agent per all international guidelines (WHO, ADA, RSSDI); reduces hepatic glucose output; weight-neutral or causes weight loss; cardioprotective; no hypoglycaemia as monotherapy; very low cost; extensive safety record |
| Dosage Form | Tablet |
| Dose | 500 mg (start), titrate to 500-1000 mg |
| Frequency | Twice daily (with meals) |
| Duration | Long-term (indefinite), with step-up if HbA1c not at target |
| Instructions | Take with food to reduce GI side effects; contraindicated in renal impairment (eGFR <30); check renal function annually; lifestyle modification is essential alongside |
H. Stage 2 Hypertension
| Step | Details |
|---|---|
| Diagnosis | Stage 2 Hypertension (BP ≥160/100 mmHg) |
| Therapeutic Objective | Reduce BP to <130/80 mmHg; prevent target organ damage (heart, kidney, brain, eyes) |
| Effective Drug Groups | ACE inhibitors, ARBs, Calcium channel blockers (CCBs), Thiazide diuretics, Beta-blockers |
| P-drug | Amlodipine (CCB) + Enalapril (ACE inhibitor) - combination recommended for Stage 2 |
| Rationale | Stage 2 HTN requires combination therapy at initiation; Amlodipine: well tolerated, once daily, proven CV outcome benefit; Enalapril: renoprotective, cardioprotective, low cost |
| Dosage Form | Tablet |
| Dose | Amlodipine 5 mg OD (up to 10 mg); Enalapril 5 mg OD (up to 40 mg) |
| Duration | Lifelong |
| Instructions | Monitor BP regularly; restrict salt (<5g/day); avoid NSAIDs; Enalapril may cause dry cough (switch to ARB - Losartan if so); check renal function and electrolytes |
I. Upper Respiratory Tract Infections (URTI)
| Step | Details |
|---|---|
| Diagnosis | Acute URTI - viral (most common: rhinovirus, coronavirus); includes common cold, viral pharyngitis |
| Therapeutic Objective | Symptomatic relief; prevent secondary bacterial complications; avoid unnecessary antibiotics |
| Effective Drug Groups | Analgesics/antipyretics (Paracetamol), Decongestants (Pseudoephedrine), Antihistamines (Chlorphenamine), Saline nasal rinse - No antibiotics for viral URTI |
| P-drug | Paracetamol |
| Rationale | Safe analgesic and antipyretic; minimal side effects; suitable for all ages including pregnant women; low cost; treats the major symptoms (fever, sore throat pain, myalgia) |
| Dosage Form | Tablet |
| Dose | 500-1000 mg |
| Frequency | Every 4-6 hours (max 4g/day) |
| Duration | 5-7 days or until symptomatic |
| Instructions | Adequate hydration; steam inhalation; rest; avoid antibiotics unless secondary bacterial infection confirmed; add Chlorphenamine 4 mg at night if rhinorrhoea/sneezing prominent |
J. Generalized Tonic-Clonic Seizures (GTCS)
| Step | Details |
|---|---|
| Diagnosis | Generalized Tonic-Clonic Seizures (epilepsy) |
| Therapeutic Objective | Complete seizure freedom; minimize drug side effects; maintain quality of life |
| Effective Drug Groups | Valproate, Phenytoin, Carbamazepine, Lamotrigine, Levetiracetam, Phenobarbitone |
| P-drug | Sodium Valproate |
| Rationale | Broad-spectrum AED - effective for all generalized seizure types; first-line for GTCS; well-established safety profile (except in women of childbearing age); affordable |
| Dosage Form | Enteric-coated tablet (Valproate CR) |
| Dose | 200-400 mg (start), titrate to 600-1200 mg/day |
| Frequency | Twice daily |
| Duration | Minimum 2-3 years seizure-free before considering withdrawal |
| Instructions | Never stop abruptly; monitor LFTs; avoid in women of childbearing age (teratogenic - neural tube defects); use Lamotrigine instead in women; take with food; check drug levels if needed |
K. Deep Vein Thrombosis (DVT)
| Step | Details |
|---|---|
| Diagnosis | Deep Vein Thrombosis (DVT) - clot in deep veins, usually lower limbs |
| Therapeutic Objective | Prevent thrombus extension; prevent pulmonary embolism; achieve recanalization; prevent recurrence |
| Effective Drug Groups | Heparins (UFH, LMWH), Vitamin K antagonists (Warfarin), DOACs (Rivaroxaban, Apixaban) |
| P-drug | Rivaroxaban (DOAC) |
| Rationale | Oral, fixed-dose, no INR monitoring required; non-inferior to LMWH+Warfarin in trials; convenient once-daily dosing; no dietary interactions unlike Warfarin |
| Dosage Form | Tablet |
| Dose | 15 mg BD with food for 3 weeks, then 20 mg OD with food |
| Duration | Minimum 3 months (provoked DVT); 6 months or longer for unprovoked or recurrent |
| Instructions | Take with meals (increases bioavailability); avoid if eGFR <15; watch for bleeding; no routine monitoring needed but check renal function periodically |
L. Hypercholesterolemia
| Step | Details |
|---|---|
| Diagnosis | Hypercholesterolemia (elevated LDL-C, primary or secondary) |
| Therapeutic Objective | Reduce LDL-C to target; prevent cardiovascular events (MI, stroke) |
| Effective Drug Groups | Statins, Bile acid sequestrants, Fibrates, Ezetimibe, PCSK9 inhibitors, Niacin |
| P-drug | Atorvastatin |
| Rationale | Most potent statin for LDL reduction (reduces LDL by 30-55%); proven cardiovascular mortality benefit; once daily dosing; generic available - low cost; first-line per all major guidelines |
| Dosage Form | Tablet |
| Dose | 10-20 mg/day (low-high CV risk), 40-80 mg/day (high CV risk) |
| Frequency | Once daily (can be taken any time of day - unlike other statins) |
| Duration | Long-term / lifelong (especially if CV risk factors present) |
| Instructions | Lifestyle modification (diet + exercise) essential alongside; monitor LFTs; warn about myopathy/rhabdomyolysis (rare); avoid grapefruit juice |
M. Herpes Simplex Keratitis
| Step | Details |
|---|---|
| Diagnosis | Herpes Simplex Keratitis (corneal infection with HSV-1) |
| Therapeutic Objective | Eliminate viral replication; reduce corneal damage; prevent recurrence and vision loss |
| Effective Drug Groups | Topical antivirals (Aciclovir eye ointment, Ganciclovir gel), Systemic antivirals (Aciclovir, Valaciclovir) |
| P-drug | Aciclovir 3% Eye Ointment (topical) |
| Rationale | Standard first-line treatment for HSV epithelial keratitis; directly applied to affected site; proven efficacy; minimal systemic absorption; safe; affordable |
| Dosage Form | Ophthalmic ointment 3% |
| Dose | 1 cm ribbon instilled into conjunctival sac |
| Frequency | 5 times daily (every 4 hours while awake) |
| Duration | 3 days after healing (total ~10-14 days) |
| Instructions | Do NOT use topical steroids alone (worsens disease); refer to ophthalmologist; use systemic Aciclovir 400 mg 5x/day if recurrent or stromal keratitis; avoid contact lenses |
N. Acute Tonsillitis
| Step | Details |
|---|---|
| Diagnosis | Acute Tonsillitis - most commonly Group A Streptococcus (GAS) or viral |
| Therapeutic Objective | Eradicate GAS; prevent complications (rheumatic fever, peritonsillar abscess); symptomatic relief |
| Effective Drug Groups | Penicillins (Amoxicillin, Phenoxymethylpenicillin), Cephalosporins, Macrolides (penicillin-allergic) |
| P-drug | Amoxicillin |
| Rationale | Drug of choice for streptococcal tonsillitis; bactericidal; narrow spectrum (minimizes resistance); oral bioavailability; low cost; tasty suspension for children |
| Dosage Form | Tablet / Capsule (or suspension for children) |
| Dose | 500 mg (adults); 25 mg/kg/day for children |
| Frequency | 3 times daily (every 8 hours) |
| Duration | 10 days (full course essential to prevent rheumatic fever) |
| Instructions | Complete the full course even if symptoms improve; add Paracetamol for fever/pain; if penicillin-allergic: use Azithromycin 500 mg OD x 3 days; adequate fluid intake |
O. Scabies
| Step | Details |
|---|---|
| Diagnosis | Scabies (infestation by Sarcoptes scabiei mite - intense itching, especially nocturnal) |
| Therapeutic Objective | Kill mites and eggs; relieve itching; prevent transmission to contacts |
| Effective Drug Groups | Topical scabicides (Permethrin 5%, Benzyl benzoate, Sulphur ointment), Systemic (Ivermectin) |
| P-drug | Permethrin 5% Cream |
| Rationale | First-line scabicide per WHO and most guidelines; single application highly effective; kills both mites and eggs; low systemic absorption; safe in children >2 months; low cost |
| Dosage Form | Topical cream 5% |
| Dose | Apply entire cream to whole body from neck downwards (all skin folds, under nails) |
| Frequency | Single application; repeat after 1 week if needed |
| Duration | Leave on for 8-12 hours (overnight), then wash off |
| Instructions | Treat all household contacts simultaneously; wash all clothing and bedding in hot water; add Chlorphenamine or Hydroxyzine for itch relief; Ivermectin 200 mcg/kg single oral dose is alternative for crusted/Norwegian scabies |
Summary Table - P-drug Choices at a Glance
| Scenario | Condition | P-Drug |
|---|---|---|
| A | Toothache | Ibuprofen 400 mg TDS |
| B | Stable Angina | GTN 0.5 mg SL (acute) + Atenolol 50 mg OD (prophylaxis) |
| C | Productive Cough | Bromhexine 8 mg TDS |
| D | Dry Cough | Dextromethorphan 15-30 mg Q6-8H |
| E | Rheumatoid Arthritis | Methotrexate 7.5-25 mg/week + Ibuprofen 400 mg TDS |
| F | DM Type 1 | Insulin (Isophane + Regular) 0.5-1 U/kg/day SC |
| G | DM Type 2 | Metformin 500-1000 mg BD |
| H | Stage 2 HTN | Amlodipine 5 mg OD + Enalapril 5 mg OD |
| I | URTI | Paracetamol 500-1000 mg Q4-6H |
| J | GTCS | Sodium Valproate 200-1200 mg/day BD |
| K | DVT | Rivaroxaban 15 mg BD x 3 weeks, then 20 mg OD |
| L | Hypercholesterolemia | Atorvastatin 10-80 mg OD |
| M | Herpes Simplex Keratitis | Aciclovir 3% Eye Ointment - 5x daily |
| N | Acute Tonsillitis | Amoxicillin 500 mg TDS x 10 days |
| O | Scabies | Permethrin 5% Cream - single overnight application |
Key P-drug Selection Criteria applied throughout (WHO framework):
- Efficacy - proven therapeutic effect for the condition
- Safety - acceptable side effect and contraindication profile
- Suitability - appropriate for the patient population and route
- Cost - affordable, widely accessible, generic preferred
This is a shared conversation. Sign in to Orris to start your own chat.